All Stories

  1. Peroral endoscopic myotomy for the management of symptomatic cricopharyngeal bar (C-POEM): a case series and video demonstration
  2. Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF Therapy in Crohn’s Disease Patients
  3. Symptomatic duodenal metastasis from a small cell lung cancer primary: a rare case
  4. Metabolic and Bariatric Endoscopy: A Mini-Review
  5. Management of a large percutaneous endoscopic gastrostomy tube-associated gastric ulcer with endoscopic suturing
  6. Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom
  7. Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn’s Disease
  8. Phenome-Wide Association Study of Drugs and Co-morbidities Associated with Gastrointestinal Dysfunction in Systemic Sclerosis
  9. Genome-Wide Methylation Profiling in 229 Patients With Crohn’s Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn’s Disease (TOPPIC)
  10. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a pr...
  11. Between progress and changing times: The journey of UEG Education Committee's chair
  12. Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID ‐19 pandemic: the PREPARE‐IBD multicentre cohort study
  13. Blood and guts
  14. Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease
  15. Diagnostic Performance of Magnetic Resonance Enterography Disease Activity Indices Compared with a Histological Reference Standard for Adult Terminal Ileal Crohn’s Disease: Experience from the METRIC Trial
  16. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
  17. Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab
  18. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in infliximab- and vedolizumab-treated patients
  19. The Relationship Between Mucosal Microbiota, Colitis, and Systemic Inflammation in Chronic Granulomatous Disorder
  20. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
  21. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
  22. Benefits of Structured Pediatric to Adult Transition in Inflammatory Bowel Disease
  23. Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients
  24. The relationship between mucosal microbiota, colitis and systemic inflammation in Chronic Granulomatous Disorder
  25. Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis
  26. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
  27. Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study
  28. Endoscopy during the peak of COVID-19 pandemic: impact on activity and financial implications for a tertiary referral center in London
  29. Editorial: fatigue—difficult to assess and difficult to treat
  30. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource
  31. UEG Guidelines framework to guide clinical practice
  32. Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic
  33. Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel
  34. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic
  35. The cost-effectiveness of radiofrequency ablation for treating patients with gastric antral vascular ectasia refractory to first line endoscopic therapy
  36. UEG Education—building on success
  37. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease
  38. Diagnosis and management of bile acid diarrhoea: a survey of UK expert opinion and practice
  39. Magnetic resonance enterography compared with ultrasonography in newly diagnosed and relapsing Crohn’s disease patients: the METRIC diagnostic accuracy study
  40. IBD BioResource: an open-access platform of 25 000 patients to accelerate research in Crohn’s and Colitis
  41. Chronic Granulomatous Disorder–Associated Colitis Can Be Accurately Evaluated with MRI Scans and Fecal Calprotectin Level
  42. Editorial: combination immunosuppressive therapy to treat Crohn’s disease - ready for all age groups?
  43. Radiological findings in gastrointestinal scleroderma
  44. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
  45. Cause or effect? Interpreting emerging evidence for dysbiosis in systemic sclerosis
  46. Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease
  47. Radiofrequency ablation for patients with refractory symptomatic anaemia secondary to gastric antral vascular ectasia
  48. In memory of Dr Tomer Adar
  49. A New Look at Familial Risk of Inflammatory Bowel Disease in the Ashkenazi Jewish Population
  50. Rare coding variant analysis in a large cohort of Ashkenazi Jewish families with inflammatory bowel disease
  51. Magnetic resonance enterography, small bowel ultrasound and colonoscopy to diagnose and stage Crohn’s disease: patient acceptability and perceived burden
  52. Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a multicentre trial
  53. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis
  54. Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine
  55. There is a need for new systemic sclerosis subset criteria. A content analytic approach
  56. PTH-041 Definitive management of a very rare cause of significant acute upper gastrointestinal bleeding: gastric lipoma resected by hybrid endoscopic submucosal dissection
  57. UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care
  58. Small bowel obstruction caused by a migrated Obalon gastric bariatric balloon: nonsurgical management by antegrade double-balloon panenteroscopy
  59. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial
  60. The role of dietary supplements in inflammatory bowel disease
  61. Small and Large Intestinal Involvement and Nutritional Issues
  62. Gallstone mimicry: a rare cause of abdominal pain
  63. Gastrointestinal manifestations of systemic sclerosis
  64. The ABC of E-learning: Utilizing E-learning resources for training and research in gastroenterology
  65. Elevated liver enzymes in inflammatory bowel disease
  66. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis
  67. P.14.3 CORRELATION BETWEEN CLINICAL RESPONSE AND ANEMIA RESOLUTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI-TNF INHIBITORS
  68. Endoscopic resection of a giant ileal inflammatory fibroid polyp by retrograde double-balloon enteroscopy
  69. Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease
  70. Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs
  71. OP-16 DIETARY INTERVENTION USING THE LOW FODMAP DIET VERSUS THE “MILK, EGG, WHEAT AND SOYA FREE” DIET FOR TREATMENT OF FUNCTIONAL GUT DISORDERS A SINGLE CENTRE EXPERIENCE
  72. Gastro-oesophageal dismotility measurements in scleroderma-associated interstitial lung disease: Correlation with respiratory and reflux symptoms
  73. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis
  74. Intractable diarrhoea despite immune reconstitution in an HIV positive man
  75. UEG E‐learning: The future has arrived
  76. Indurated plaques on the penis
  77. Gut symptoms in diabetics correlate with components of the rectoanal inhibitory reflex, but not with pudendal nerve motor latencies or systemic autonomic neuropathy
  78. PTH-056 Trial to assess cannabidiol in the symptomatic treatment of ulcerative colitis
  79. Hepatic portal venous gas and portal venous thrombosis following colonoscopy in a patient with terminal ileal Crohn's disease
  80. Irritable bowel syndrome
  81. Travel health and pretravel preparation in the patient with inflammatory bowel disease
  82. Sa1264 A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centred Pilot Study to Assess the Symptomatic Treatment of Ulcerative Colitis With Cannabidiol
  83. A rare cause of abdominal pain, diarrhoea and GI bleeding
  84. UEG Education: time to shape the future
  85. METRIC (MREnterography or ulTRasound in Crohn’s disease): a study protocol for a multicentre, non-randomised, single-arm, prospective comparison study of magnetic resonance enterography and small bowel ultrasound compared to a reference standard in tho...
  86. CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis
  87. OC-055 Ibd Passport-developing An Evidence-based Internet Travel Resource For Inflammatory Bowel Disease: A Report Of The Initial Stages Of Implementation
  88. PTU-092 Patient And Professionals Perceptions Of Travel Behaviour In Inflammatory Bowel Disease
  89. PWE-115 Patients Continue To Travel Abroad Despite Recently Active Disease And Travel Concerns: Results Of A Single Centre Study In Inflammatory Bowel Disease And Travel
  90. PWE-183 Preliminary Significant Findings From A Randomised Control Trial Of Posterior Tibial Nerve Stimulation In Systemic Sclerosis Associated Faecal Incontinence
  91. P574 A recent flare of disease does not prohibit travel: early results of a single centre study in inflammatory bowel disease and travel
  92. P553 A single-centre pilot study examining internet use for health related information among patients with inflammatory bowel disease
  93. Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management
  94. Using an ‘action set’ for the management of acute upper gastrointestinal bleeding
  95. Bloody Diarrhoea
  96. Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNFα therapy
  97. PTH-132 Iron Deficiency Anaemia Nurse Led Clinic: Audit of 1st Year
  98. P57 Comparative Cost-Effectiveness of IGRA to Detect Latent TB Infection in UK Inflammatory Bowel Disease Patients Initiating Anti-TNFα Agents: Abstract P57 Table 1
  99. Weight loss and lumbosacral back pain in a 79-year-old Indian man
  100. Malignant mimicry—a 17-year-old with abdominal pain and weight loss
  101. PTU-113 Quality of life in patients with ileoanal pouch: a survey comparing two different patient populations
  102. PTU-096 The use of commercial interferon-γ release assays to screen for mycobacterial infection in inflammatory bowel disease patients initiating anti-TNF agents
  103. Irritable bowel syndrome
  104. Influence of smoking and other environmental factors in inflammatory bowel disease activity: what do our patients think?
  105. Iron deficiency anaemia is common in patients with an ileoanal pouch and is not always associated with inflammation
  106. There will be blood... a complete audit cycle
  107. Images of the terminal ileum are more convincing than cecal images for verifying the extent of colonoscopy
  108. Attitudes and Experiences of Adolescents in an Innovative IBD Transition Service
  109. Amitriptyline modifies the visceral hypersensitivity response to acute stress in the irritable bowel syndrome
  110. The effect of Khat (Catha edulis) as an appetite suppressant is independent of ghrelin and PYY secretion
  111. Acid-related oesophageal sensitivity, not dysmotility, differentiates subgroups of patients with non-erosive reflux disease
  112. Gastrointestinal Manifestations of Systemic Sclerosis
  113. Pharmacological modulation of gut mucosal and large vessel blood flow
  114. Reaping value from intellectual property: DuPont's strategic approach achieves global growth
  115. Ghrelin augments afferent response to distension in rat isolated jejunum
  116. The effect of different macronutrient infusions on appetite, ghrelin and peptide YY in parenterally fed patients
  117. Diabetes and the Gastrointestinal System
  118. Prokineticin-2, motilin, ghrelin and metoclopramide: Prokinetic utility in mouse stomach and colon
  119. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study
  120. Effect of acute physical and psychological stress on gut autonomic innervation in irritable bowel syndrome
  121. Sporadic duodenal adenoma is associated with colorectal neoplasia
  122. Ghrelin for the gastroenterologist: history and potential
  123. Biofeedback, not laxatives, improves symptoms, transit and autonomic tone in functional constipation
  124. Medical management of diverticular disease
  125. Colonic Disorders